BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Contrave (naltrexone/bupropion) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Contrave (naltrexone/bupropion)\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05919797-126@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Contrave (naltrexone/bupropion): Phase 4 readout est. (NCT05919797)
DESCRIPTION:Contrave (naltrexone/bupropion)\, phase 4\, Obesity.\nStudy: We
 ight Loss Study: Genetics and Response to Naltrexone/Bupropion\nEstimated 
 primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/naltrexone-bupropion#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05919797
URL:https://assetmemo.bio/drug/naltrexone-bupropion#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06845345-126@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Contrave (naltrexone/bupropion): Phase 4 readout est. (NCT06845345)
DESCRIPTION:Contrave (naltrexone/bupropion)\, phase 4\, Obesity.\nStudy: Ef
 fect of an Early Time Restricted Eating Mediterranean Diet Compared to Nal
 trexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Fa
 ctors in a Hospital Outpatient Clinic (MEDFAST-study)\nEstimated primary c
 ompletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /naltrexone-bupropion#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06845345
URL:https://assetmemo.bio/drug/naltrexone-bupropion#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06620562-126@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Contrave (naltrexone/bupropion): Phase 4 readout est. (NCT06620562)
DESCRIPTION:Contrave (naltrexone/bupropion)\, phase 4\, Obesity.\nStudy: Im
 proving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extende
 d-release Tablet\nEstimated primary completion: June 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/naltrexone-bupropion#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06620562
URL:https://assetmemo.bio/drug/naltrexone-bupropion#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06098079-126@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Contrave (naltrexone/bupropion): Phase 4 readout est. (NCT06098079)
DESCRIPTION:Contrave (naltrexone/bupropion)\, phase 4\, Obesity.\nStudy: Ef
 fect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combina
 tion (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)\
 nEstimated primary completion: January 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/naltrexone-bupropion#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06098079
URL:https://assetmemo.bio/drug/naltrexone-bupropion#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
